Navigation Links
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights
Date:2/12/2010

- Payment to Bioniche of US$8M by Endo Pharmaceuticals -

BELLEVILLE, ON, Feb. 12 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals ( ENDP) for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America. The achievement of these milestones triggers a total payment of US$8 million to Bioniche from Endo.

Endo Pharmaceuticals has also elected to exercise its option for exclusive rights to develop and market the product globally. As a result of the decision, Endo will all assume all external development expenses for the product.

"We are pleased with this decision by Endo," stated Graeme McRae, Chairman, President and CEO of Bioniche Life Sciences Inc. "We look forward to ongoing collaboration in addressing the global market opportunity for our bladder cancer product, as well as effectively completing the clinical development program and achieving product registrations in global jurisdictions."

Under the licensing agreement, Bioniche has the potential to receive a total of US$110 million in payments associated with the achievement of certain clinical, regulatory and commercial milestones. The achievement of the first milestone of US$6 million was announced by the Company in November 2009. Future milestones will be announced as they are achieved and, with its exclusive manufacturing supply contract, Bioniche will also receive a net-sales-based revenue stream upon product approval.

Bioniche's patented intravesical formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed for the treatment of non-muscle-invasive bladder cancer (Urocidin(TM)) is undergoing a U.S. Food and Drug Administration (FDA) fast tracked Phase III registration study of the product for the treatment-refractory indication. Future plans to further develop Urocidin(TM) are being defined and will be disclosed by Endo.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP
2. Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
3. Bioniche Reports Fiscal 2009 Year-End Results
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
5. Bioniche Repays Revolving Credit Facility
6. Bioniche Provides a Corporate Update
7. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
8. Bioniche Represented at House of Commons Sub-Committee on Food Safety
9. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
10. Bioniche Reports Fiscal 2009 Third Quarter
11. Bioniche Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples ... the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare ... Center is an exciting addition to our provider network, and the addition will ...
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting ... Challenge , the Cradle to Cradle Products Innovation Institute has announced. , ... run through early 2018. The challenges are presented by the Institute in partnership with ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Neil H. Greco ... planning assistance to communities throughout the region, is launching a charity drive to raise ... is by far the deadliest killer in America, and is responsible for 1 in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Edwards Lifesciences Corporation ... patient-focused innovations for structural heart disease and critical care ... quarter ended December 31, 2016 after the market closes ... conference call at 5:00 p.m. ET that day to ... conference call, dial (877) 407-8037 or (201) 689-8037.  For ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. 17, 2017 ... selected Velos and its flagship technology platform Velos ... initiatives. CHNC is a benchmarking and ... Care Units at leading children,s hospitals across ... a benchmark of care and short-term outcomes for ...
(Date:1/17/2017)... , January 17, 2017 ReportsnReports.com adds ... report provides an overview of the Anaphylaxis,s therapeutic pipeline with ... comparative analysis at various stages, therapeutics assessment by drug target, ... type, along with latest updates, and featured news and press ... ...
Breaking Medicine Technology: